Ageing – Pipeline Review, 2020

Ageing is a natural process in which structural and functional changes accumulate in an organism over the period of time. According to the United Nations, the proportion of the aged population is increasing in almost every corner of the world. Additionally, as per estimates given by the United Nations, an estimated 962 million people across the globe were above 60 years which accounted for an estimated 13.0% of the global population in 2017. Though aging is a natural process, researchers and pharmaceutical companies are working in collaboration to develop drugs which will delay the process of aging as well as the effect of aging on the human body. 

At the present situation, there is no drug available to cure ageing. Pharmaceutical companies and academic & research institutes are prominently focusing on studying and developing new treatment options for the Ageing. For instance; Rapamycin, which is being studied by AgelessRx is currently in the phase-4 of the clinical trials to check its efficacy and tolerability as anti-aging agents in the geriatric population.

To know how our report can help streamline your business, Speak to Analyst

At present around 66% of the pipeline candidates for ageing are in the phase-1 and phase-2 stage. Majority of the studies have been sponsored by academic and research institutes coupled with some pharmaceutical companies.

Report Description

The report on ‘Ageing – Pipeline Review, 2020’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Ageing. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Ageing.

The report on ‘Ageing – Pipeline Review, 2020’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Ageing


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for Ageing


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary